Holen Sie sich die Stockscreener-App
2.06
1.98%
0.04
Schlusskurs vom Vortag:
$2.02
Offen:
$2.08
24-Stunden-Volumen:
17,777
Relative Volume:
0.17
Marktkapitalisierung:
$104.18M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.48M
KGV:
-15.04
EPS:
-0.137
Netto-Cashflow:
$-5.30M
1W Leistung:
+0.98%
1M Leistung:
-8.85%
6M Leistung:
-41.48%
1J Leistung:
+0.00%
1-Tages-Spanne:
$2.01
$2.12
1-Wochen-Bereich:
$1.90
$2.12
52-Wochen-Spanne:
$1.85
$33.90
Polaryx Therapeutics Inc Stock (PLYX) Company Profile
Firmenname
Polaryx Therapeutics Inc
Sektor
Branche
Telefon
201-940-7236
Adresse
140 EAST RIDGEWOOD AVENUE, PARAMUS
Compare PLYX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLYX
Polaryx Therapeutics Inc
|
2.09 | 100.69M | 0 | -6.48M | -5.30M | -0.137 |
VRTX
Vertex Pharmaceuticals Inc
|
521.32 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
802.44 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.73 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.36 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.19 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Polaryx Therapeutics Inc Stock (PLYX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-27 | Eingeleitet | Maxim Group | Buy |
Polaryx Therapeutics Inc Aktie (PLYX) Neueste Nachrichten
Polaryx Therapeutics, Inc. (NASDAQ:PLYX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Polaryx Therapeutics (PLYX) Stock Analysis Report | Financials & Insights - Benzinga España
Polaryx Therapeutics (PLYX) Slips 0.49% to $2.03, Support Holds at $1.93Ease of Movement - vinanet.vn
Polaryx Therapeutics Appoints Will Charlton as Chief Medical Officer Starting September 1, 2026 - Kalkine Media
Polaryx Therapeutics Appoints New Chief Medical Officer - TipRanks
Polaryx Therapeutics Names Will Charlton CMO Ahead of Phase 2 SOTERIA Trial - citybiz
Polaryx appoints Will Charlton as chief medical officer - Investing.com
Polaryx raises $10M for phase II rare disease basket trial - BioWorld News
Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer - The Manila Times
A pediatric doctor with over 15 years’ experience joins Polaryx - Stock Titan
Polaryx appoints Will Charlton as chief medical officer By Investing.com - Investing.com South Africa
PLYX Stock Rockets To Best Day Ever: Why Retail Traders Are Piling Into This Battered Biotech - Stocktwits
Polaryx advances preparations for Phase 2 trial launch in Q4 By Investing.com - Investing.com Nigeria
Polaryx advances preparations for Phase 2 trial launch in Q4 - Investing.com India
Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial - The Manila Times
Polaryx plans to test one oral drug across four childhood diseases - Stock Titan
Polaryx (PLYX) Market: Moves 9.66% Lower to $1.87 in the Current Update; the Supplied Trading Band Runs From $1.78 to $1.96 in Latest TradingShort Term Trading Ideas - siam.in
We Think Polaryx Therapeutics (NASDAQ:PLYX) Can Afford To Drive Business Growth - Sahm
This Vail Resorts Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Sahm
Analysts Offer Insights on NA Companies: SpaceX (SPCX) and Polaryx Therapeutics, Inc. (PLYX) - The Globe and Mail
Polaryx Therapeutics (PLYX) cuts losses as cash rises to $11.5M - Stock Titan
Polaryx Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Raymond James Initiates Polaryx Therapeutics(PLYX.US) With Buy Rating, Announces Target Price $6 - Moomoo
Polaryx Therapeutics, Inc. (NASDAQ:PLYX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Polaryx Therapeutics (NASDAQ:PLYX) Coverage Initiated at Raymond James Financial - MarketBeat
PLYX Initiated Coverage by Raymond James -- Strong Buy Rating An - GuruFocus
Raymond James Initiates Polaryx Therapeutics at Strong Buy - marketscreener.com
Raymond James initiates Polaryx Therapeutics stock with strong buy By Investing.com - Investing.com South Africa
Raymond James initiates Polaryx Therapeutics stock with strong buy - Investing.com India
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference - 富途牛牛
Polaryx Therapeutics Ord Shs (PLYX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Polaryx Therapeutics, Inc. Common Stock (NASDAQ: PLYX) Stock Price, News & Analysis - Kalkine
Polaryx Therapeutics (PLYX) sets 2026 virtual meeting, director votes and auditor - Stock Titan
PLYX Initiates Coverage On by Lucid Capital Markets -- Rating Se - GuruFocus
PLYX Initiates Coverage On by Lucid Capital Markets -- Rating Set to Buy - GuruFocus
Lucid Capital initiates Polaryx stock with buy rating on rare disease therapy potential - Investing.com Canada
PLYX|Polaryx Therapeutics Ord Shs|Price:2.096|Chg%:-0.024 - TradingKey
Polaryx Therapeutics, Inc. Revenue Breakdown – NASDAQ:PLYX - TradingView
Polaryx Therapeutics Ord Shs (PLYX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PLYX|Polaryx Therapeutics Ord Shs|Price:2.090|Chg%:-0.010 - TradingKey
Polaryx Therapeutics, Inc. Revenue Breakdown – BOATS:PLYX - TradingView
Polaryx Therapeutics Announces Chief Medical Officer Resignation - The Globe and Mail
Polaryx Therapeutics, Inc. Files Form 8-K as Emerging Growth Company on NASDAQ (PLYX) – July 2026 - Minichart
Polaryx Therapeutics' Lisa Bollinger resigns as Chief Medical Officer - TradingView
Polaryx Therapeutics, Inc. Announces Resignation of Lisa Bollinger from Chief Medical Officer, Effective July 19, 2026 - marketscreener.com
Polaryx Sets 2026 Virtual Annual Shareholder Meeting - TipRanks
Polaryx Therapeutics (PLYX) schedules 2026 virtual annual meeting and proposal deadline - Stock Titan
Polaryx Therapeutics (PLYX) Edges Higher Amidst Narrow Trading RangeDouble Top - vinanet.vn
What is HC Wainwright's Forecast for PLYX Q2 Earnings? - MarketBeat
Polaryx Therapeutics (NASDAQ:PLYX) Downgraded by Wall Street Zen to "Sell" - MarketBeat
PLYX News Today | Why did Polaryx Therapeutics stock drop today? - MarketBeat
Finanzdaten der Polaryx Therapeutics Inc-Aktie (PLYX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.69%
3.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):